The Department of Health and Human Services submitted an interim access policy for peptide compounding to the White House Office of Management and Budget on October 15, 2026

Evolving US policy battles over drug pricing and healthcare affordability, tracking legislation, court rulings, regulatory actions, and industry responses shaping costs, access, and market dynamics.